One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1093/annonc/mdz394.027
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 57 |  License type: elsevier-specific: oa user license |
Affiliation: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Agios Pharmaceuticals (United States), CRUK Lung Cancer Centre of Excellence, University College London, University of California, San Francisco, UW Carbone Cancer Center, Seoul National University Hospital, University of Chicago, University of Manchester, The Christie NHS Foundation Trust, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Utah Cancer Specialists, Dana-Farber Cancer Institute, Hospital Universitario 12 De Octubre, University of Washington, Harvard University, Massachusetts General HospitalLBA10_PR - ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
